Literature DB >> 19134057

Acute colonic ischaemia in rats results in long-term structural changes without alterations of colonic sensitivity.

Anna Ravnefjord1, Madeleine Pettersson, Erika Rehnström, Vicente Martinez.   

Abstract

Colonic ischaemia and mast cells have been involved in the pathophysiology of the functional gastrointestinal disorder irritable bowel syndrome, although the cause-effect relationships remain unknown. We assessed long-term histopathological and functional changes associated to an acute ischaemic episode (1 h) of the colon, followed by 8-week recovery, in rats. Functional colonic alterations [sensitivity during colorectal distension (CRD), compliance and propulsive motility] were assessed regularly during the recovery. Colonic histopathology (presence of inflammation, morphometric alterations and variations in neuronal density in the enteric nervous system) 8-week postischaemia was assessed. Following ischaemia, none of the functional parameters tested (motility, sensitivity and compliance) were affected. At necropsy, the colon presented an overall normal appearance with an increase in weight of the ischaemic area (mg/cm: 99 +/- 6; P < 0.05 vs. control: 81 +/- 4 or sham ischaemia: 81 +/- 3). Histopathological evaluations revealed the presence of a local infiltrate of mast cells in the area of ischaemia (nb of mast cells: 142 +/- 50; P < 0.05 vs. control, 31 +/- 14 or sham ischaemia: 40 +/- 16), without other significant alterations. Animals subjected to colonic ischaemia and treated 8 weeks later with the mast cell degranulator, compound 48/80, showed no changes in CRD-related pain responses. These studies show that acute colonic ischaemia is associated with the presence of a long-term local infiltration of mast cells, located within the serosa and muscle layers, despite the absence of functional changes, including colonic sensitivity. Considering the important pathophysiological functions of mast cells, the observed mast cell infiltration may be involved in ischaemia-induced functional changes yet to be characterized.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19134057      PMCID: PMC2669609          DOI: 10.1111/j.1365-2613.2008.00623.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  41 in total

1.  Assessment of visceral pain-related pseudo-affective responses to colorectal distension in mice by intracolonic manometric recordings.

Authors:  Susanne Arvidsson; Marie Larsson; Håkan Larsson; Erik Lindström; Vincente Martinez
Journal:  J Pain       Date:  2006-02       Impact factor: 5.820

2.  Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.

Authors:  Giovanni Barbara; Bingxian Wang; Vincenzo Stanghellini; Roberto de Giorgio; Cesare Cremon; Giovanni Di Nardo; Marcello Trevisani; Barbara Campi; Pierangelo Geppetti; Marcello Tonini; Nigel W Bunnett; David Grundy; Roberto Corinaldesi
Journal:  Gastroenterology       Date:  2007-01       Impact factor: 22.682

Review 3.  Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment.

Authors:  William D Chey; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2006-08

Review 4.  Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

Authors:  Lin Chang; William D Chey; Lucinda Harris; Kevin Olden; Christina Surawicz; Philip Schoenfeld
Journal:  Am J Gastroenterol       Date:  2006-05       Impact factor: 10.864

5.  Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats.

Authors:  Richard Róka; Afifa Ait-Belgnaoui; Christel Salvador-Cartier; Raphael Garcia-Villar; Jean Fioramonti; Hélène Eutamène; Lionel Bueno
Journal:  Gut       Date:  2007-02-19       Impact factor: 23.059

6.  Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.

Authors:  Jung Ho Park; Poong-Lyul Rhee; Hyun Seo Kim; Jun Haeng Lee; Young-Ho Kim; Jae Jun Kim; Jong Chul Rhee
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

7.  Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis.

Authors:  D-C Suh; K H Kahler; I-S Choi; H Shin; J Kralstein; M Shetzline
Journal:  Aliment Pharmacol Ther       Date:  2007-03-15       Impact factor: 8.171

8.  Alteration of CCK-induced satiety in post-Nippostrongylus brasiliensis-infected rats.

Authors:  Jérôme Gay; Lucien Ressayre; Rafael Garcia-Villar; Lionel Bueno; Jean Fioramonti
Journal:  Brain Behav Immun       Date:  2003-02       Impact factor: 7.217

Review 9.  Mechanisms of hypersensitivity in IBS and functional disorders.

Authors:  F Azpiroz; M Bouin; M Camilleri; E A Mayer; P Poitras; J Serra; R C Spiller
Journal:  Neurogastroenterol Motil       Date:  2007-01       Impact factor: 3.598

10.  The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats.

Authors:  Erika Käll; Erik Lindström; Vicente Martinez
Journal:  Eur J Pharmacol       Date:  2007-06-05       Impact factor: 4.432

View more
  1 in total

Review 1.  The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Authors:  James H Lewis
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.